Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Leukemia

    Tampa, FL

    Search
    Leukemia
    Tampa, FL
    Show Map
    Map View
    Tampa, FL
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      145 Leukemia Trials near Tampa, FL

      Power is an online platform that helps thousands of Leukemia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Lenalidomide + Blinatumomab for Lymphoma

      Tampa, Florida
      This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed). Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Uncontrolled Illness, Others
      Must Not Be Taking:Efavirenz, Stavudine, Zidovudine

      44 Participants Needed

      AG-120 for Blood Cancers

      Tampa, Florida
      The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Additionally, the study includes a substudy evaluating the safety and tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of AG-120 in subjects with relapsed or refractory myelodysplastic syndrome with an IDH1 mutation. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Recent HSCT, Severe Infection, Heart Failure, Others
      Must Not Be Taking:QT Prolonging Drugs

      291 Participants Needed

      Larotrectinib for TRK Fusion Cancers and Acute Leukemia

      Tampa, Florida
      This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:< 30

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, High Grade Gliomas, Others
      Must Not Be Taking:CYP3A4 Inducers, CYP3A4 Inhibitors

      33 Participants Needed

      Chemotherapy for Acute Myeloid Leukemia in Young Patients with Down Syndrome

      Tampa, Florida
      This trial studies a chemotherapy treatment that adjusts based on how well patients respond initially. It targets younger patients with Down syndrome who have certain types of blood cancer. The treatment aims to effectively kill cancer cells while reducing side effects.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:91 - 3

      Key Eligibility Criteria

      Disqualifiers:Promyelocytic Leukemia, Prior Therapy, Others

      280 Participants Needed

      Lenalidomide +/− Epoetin Alfa for Myelodysplastic Syndrome

      Tampa, Florida
      This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cells. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Uncontrolled Hypertension, HIV, Others
      Must Be Taking:Lenalidomide

      247 Participants Needed

      CBX-250 for Acute Myeloid Leukemia

      Tampa, Florida
      Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS and CMML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B, Cardiac Disease, Others
      Must Not Be Taking:Anti-leukemic Therapy

      72 Participants Needed

      AUTX-703 for Acute Myeloid Leukemia and Myelodysplastic Syndrome

      Tampa, Florida
      This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Other Malignancy, HIV, Others
      Must Not Be Taking:CYP3A4 Inhibitors, P-gp Inhibitors

      69 Participants Needed

      Chemotherapy for Leukemia and Lymphoma

      Tampa, Florida
      This partially randomized phase III trial studies the side effects of different combinations of risk-adapted chemotherapy regimens and how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:1 - 30

      Key Eligibility Criteria

      Disqualifiers:CNS3 Leukemia, Testicular Leukemia, Pregnancy, Others
      Must Not Be Taking:Cytotoxic Chemotherapy

      9350 Participants Needed

      BGB-11417 for Acute Myeloid Leukemia and Myelodysplastic Syndrome

      Tampa, Florida
      This trial tests a new drug, BGB-11417, alone and with azacitidine, in patients with certain blood cancers to see if it is safe and effective, and to find the best dose.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Acute Promyelocytic Leukemia, Others
      Must Not Be Taking:B-cell Lymphoma-2 Inhibitors

      260 Participants Needed

      KPT-8602 for Multiple Myeloma

      Tampa, Florida
      This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), acute myeloid leukemia (AML) and newly diagnosed intermediate/high-risk MDS. Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      277 Participants Needed

      BAL0891 + Chemotherapy for Solid Tumors

      Tampa, Florida
      This trial tests a new drug, BAL0891, given to patients with severe cancer. It aims to find a safe and effective amount, both alone and with other cancer treatments. The goal is to determine the best amount that patients can handle.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Acute Promyelocytic Leukemia, Others

      260 Participants Needed

      DR-01 for Leukemia and Lymphoma

      Tampa, Florida
      This trial is testing a new drug called DR-01 to see if it is safe and effective for adults with specific blood cancers. The study will check if the drug can safely reach and affect cancer cells to stop their growth.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, CNS Malignancy, HIV, Others
      Must Not Be Taking:Systemic Corticosteroids, Immunosuppressive Drugs

      69 Participants Needed

      BGB-16673 for B-Cell Cancers

      Tampa, Florida
      This trial tests a new drug called BGB-16673 to find the best dose for patients. It aims to determine how well the drug works and its safety. The study involves finding the right dose and expanding testing to more patients.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Prior Malignancy, CNS Involvement, Others
      Must Be Taking:BTK Inhibitors

      614 Participants Needed

      Epcoritamab Combo for Non-Hodgkin's Lymphoma

      Tampa, Florida
      This trial tests a new drug called epcoritamab, given with other cancer drugs, to treat adults with Non-Hodgkin lymphoma. The study aims to see if this combination is safe and effective. Participants will have periodic health evaluations to monitor their health and the treatment's impact.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Prior Epcoritamab, Unresolved Toxicities, Others
      Must Be Taking:Anti-neoplastic Agents

      565 Participants Needed

      Venetoclax + CLAG-M for AML

      Tampa, Florida
      This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Venetoclax Refractory, CNS Involvement, Others
      Must Not Be Taking:Investigational Agents

      52 Participants Needed

      Ruxolitinib for Chronic Myelomonocytic Leukemia

      Tampa, Florida
      This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patients with CMML.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Metastatic Malignancy, Serious Illness, Others
      Must Not Be Taking:Cytotoxic Agents, GM-CSF

      29 Participants Needed

      Siltuximab for Leukemia

      Tampa, Florida
      This trial is testing siltuximab, a drug that blocks a protein to help treat a rare blood cancer called LGLL. The goal is to see if it is safe and effective for these patients. Siltuximab has shown promise in treating multiple myeloma, B-cell non-Hodgkin lymphoma, and Castleman disease, leading to its approval for Castleman disease by the FDA.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Early Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active Infection, MDS, Pregnancy, Others
      Must Not Be Taking:Methotrexate, Cyclophosphamide, Cyclosporine

      6 Participants Needed

      XmAb18968 for Leukemia

      Tampa, Florida
      This is a phase 1, dose-escalation study (using 3 + 3 dose-limiting toxicity (DLT) criteria) evaluating the safety and tolerability of XmAb18968, as well as establishing a recommended phase II dose (RP2D) in subjects with T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic (lymphoma) T-LBL (Group A) and acute myeloid leukemia (AML) (Group B).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      22 Participants Needed

      Orca-T for Blood Cancers

      Tampa, Florida
      This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies. This posting represents the Phase III component of Precision-T. The Precision-T Ph1b component is described under NCT04013685.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Prior Allogeneic HCT, HIV, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressive Therapy

      187 Participants Needed

      GVHD-Reduction Strategies for Blood Cancers

      Tampa, Florida
      This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:1 - 60

      Key Eligibility Criteria

      Disqualifiers:CNS Involvement, HIV, Uncontrolled Infections, Organ Dysfunction, Pregnancy, Others
      Must Not Be Taking:Checkpoint Inhibitors

      120 Participants Needed

      Why Other Patients Applied

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Leukemia Trial

      Fedratinib for Leukemia

      Tampa, Florida
      The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Encephalopathy, Liver Disease, Others
      Must Not Be Taking:Chemotherapy, Immunomodulatory, Ruxolitinib, Others

      25 Participants Needed

      Duvelisib + BMS-986345 for Lymphoma

      Tampa, Florida
      The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      14 Participants Needed

      Bone Marrow Transplant for Leukemia

      Tampa, Florida
      This trial is testing the safety of using bone marrow from a deceased donor to treat patients with severe leukemia. The goal is to see if this new bone marrow can help produce healthy blood cells. Patients will be monitored closely for any side effects and overall effectiveness over several months.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Living Donor, Prior HCT, Pregnancy, Infections, Others
      Must Not Be Taking:Investigational Drugs

      12 Participants Needed

      Autologous Immune Cell Therapy for Leukemia

      Tampa, Florida
      This trial uses a patient's own enhanced immune cells to treat CLL/SLL that has come back despite standard treatments. The process involves collecting the patient's immune cells, enhancing them in a lab, and then reinfusing them to help fight the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      70 Participants Needed

      Enasidenib for Acute Myeloid Leukemia

      Tampa, Florida
      This phase I trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      35 Participants Needed

      CAR-T Therapy for Acute Lymphoblastic Leukemia

      Tampa, Florida
      This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Infections, Cardiac Disease, CNS Disorders, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressives

      60 Participants Needed

      Avapritinib + Decitabine for Systemic Mastocytosis

      Tampa, Florida
      Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a concern. In this study, investigators aim to study the safety and tolerability of combined avapritinib and decitabine for the treatment of SM-AHN.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:AML, Seizure Disorder, Pregnancy, Others
      Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers

      34 Participants Needed

      CalPeg + Chemotherapy for Acute Lymphoblastic Leukemia

      Tampa, Florida
      The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:CNS Leukemia, Down Syndrome, Active Infection, Others
      Must Be Taking:Multi-agent Chemotherapy

      7 Participants Needed

      Vyxeos + Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

      Tampa, Florida
      The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:APL, CNS Leukemia, Severe Liver Disease, Others
      Must Not Be Taking:Investigational Drugs

      18 Participants Needed

      Gamma Delta T-Cell Infusion for Acute Myeloid Leukemia

      Tampa, Florida
      The purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion after an allogeneic hematopoietic cell transplant (alloHCT) to treat patients with Acute Myeloid Leukemia (AML).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active GVHD, Uncontrolled Infection, Others
      Must Not Be Taking:Systemic Glucocorticoids

      20 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Leukemia clinical trials in Tampa, FL pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Leukemia clinical trials in Tampa, FL work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Leukemia trials in Tampa, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Tampa, FL for Leukemia is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Tampa, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Leukemia medical study in Tampa, FL?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Leukemia clinical trials in Tampa, FL?

      Most recently, we added Asciminib for Acute Lymphoblastic Leukemia, CBX-250 for Acute Myeloid Leukemia and Pirtobrutinib for Chronic Lymphocytic Leukemia to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Florida

      Anxiety Clinical Trials in Florida

      Schizophrenia Clinical Trials in Florida

      ADHD Clinical Trials in Florida

      Bipolar Disorder Clinical Trials in Florida

      Multiple Sclerosis Clinical Trials in Florida

      Autism Clinical Trials in Florida

      Treatment Resistant Depression Clinical Trials in Florida

      Borderline Personality Disorder Clinical Trials in Florida

      Social Anxiety Disorder Clinical Trials in Florida

      Parkinson's Disease Clinical Trials in Florida

      Alzheimer's Disease Clinical Trials in Florida

      By Location

      Clinical Trials near Miami, FL

      Clinical Trials near Tampa, FL

      Clinical Trials near Jacksonville, FL

      Clinical Trials near Orlando, FL

      Clinical Trials near Gainesville, FL

      Clinical Trials near St. Petersburg, FL

      Clinical Trials near Fort Lauderdale, FL

      Clinical Trials near West Palm Beach, FL

      Clinical Trials near Fort Myers, FL

      Clinical Trials near Clearwater, FL

      Clinical Trials near Hollywood, FL

      Clinical Trials near Sarasota, FL

      Other People Viewed

      By Subject

      Top Clinical Trials near Maryland

      20 Autism Trials near Baltimore, MD

      25 Bipolar Disorder Trials near Fort Worth, TX

      18 Glaucoma Trials near Ventura, CA

      208 Clinical Trials near Eugene, OR

      Top Clinical Trials near Pennsylvania

      Top Cholangiocarcinoma Clinical Trials

      Top Clinical Trials near Burlington, VT

      Top Pulmonary Hypertension Clinical Trials

      Top Gastric Adenocarcinoma Clinical Trials

      Top Clinical Trials near Garland, TX

      Top Bone Cancer Clinical Trials

      By Trial

      Shoulder Pacemaker for Shoulder Injuries

      Hypofractionated Radiotherapy for Breast Cancer

      ARN-509 +/− Abiraterone for Prostate Cancer

      Lower INR Warfarin for Mechanical Valve Patients

      Stress Reduction for Heart Disease

      BV-AVD for Hodgkin's Lymphoma

      Tranexamic Acid vs Thrombin for Skin Graft Complications

      Electroporation + Immunotherapy for Pancreatic Cancer

      Digital Engagement for Heart Disease

      OSI-774 + Chemotherapy for Head and Neck Cancer

      Combination Therapy + BPA for Thromboembolic Pulmonary Hypertension

      bb2121 for Multiple Myeloma